Lungs News and Research

RSS

UNSW-developed nanoparticle could improve effectiveness of chemotherapy for neuroblastoma

In a world-first, researchers from the Australian Centre for Nanomedicine at the University of New South Wales (UNSW) in Sydney have developed a nanoparticle that could improve the effectiveness of chemotherapy for neuroblastoma by a factor of five.

21 Nov 2012

Scientists uncover new role for TLR4 in development of tissue fibrosis or scarring

An international multi-disciplinary research team led by Northwestern Medicine scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.

21 Nov 2012

HeartWare receives FDA approval for new left ventricular assist device

The U.S. Food and Drug Administration today approved the HeartWare Ventricular Assist System, a left ventricular assist device (LVAD), to support heart function and blood flow in patients with end-stage heart failure who are awaiting a heart transplant.

21 Nov 2012

Facts about Homecare

Millions of seniors and people living with disabilities will enjoy Thanksgiving and other holidays in the comfort and safety of their own homes thanks to home medical equipment and services such as oxygen therapy, hospital beds, and wheelchairs.

21 Nov 2012

Acute cough should raise asthma alarm

Around one-fifth of patients consulting their primary care physician for acute cough could have undiagnosed asthma or chronic obstructive pulmonary disease, show the results of a pan-European study.

20 Nov 2012

Pediatric TB under-diagnosed, treated, MSF report says

According to a new report released by Medecins Sans Frontieres (MSF) at the Union World Conference on Lung Health in Kuala Lumpur, many tuberculosis (TB) programs "under-diagnose, under-treat or completely leave children with TB out, despite the increase in pediatric TB, and rising numbers of children who are infected with drug-resistant forms of TB strains," PlusNews reports.

20 Nov 2012

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

USPTO issues Notice of Allowance to Sanovas’ nested balloon catheter

Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's nested balloon catheter for localized drug delivery, a component of Sanovas' Vas Zeppelin Smart Catheter technology portfolio.

20 Nov 2012

St. Jude Medical’s Portico transcatheter heart valve receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval for its 23 mm Portico Transcatheter Aortic Heart Valve and Transfemoral Delivery System.

20 Nov 2012

Illuminate PatientView to be introduced at Radiological Society of North America meeting

Illuminate PatientView, the newest application of Softek Illuminate's search engine and data aggregation technology, will be introduced at the Radiological Society of North America's annual meeting Nov. 25-30 at Chicago's McCormick Place and demonstrated by Softek associates in booth 9141.

20 Nov 2012

Combination of perifosine and temsirolimus shows promise against malignant glioma

Aeterna Zentaris Inc. today announced that perifosine, its oral AKT inhibitor, combined with temsirolimus ("TEM"), was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma ("MG").

20 Nov 2012

CFFT announces major expansion of research collaboration with Pfizer

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508.

20 Nov 2012